ETV6, 60 Ewing sarcoma, 83, 84, 153, 257, 274, 293, 297 EWS-WT1, 274 Extrophy, 129, 130 F Factor VIII, 64, 71, 109, 268 Familial renal cell carcinoma, 15 FAS, 197, 226 FGFR3, 113, 120, 122, 123 FH, 15, 18-20 FHIT, 225 Fibroadenoma, 214 Fibroepithelial polyps, 153, 156 Fibrofolliculoma, 15, 20 Fibroma, 209, 218, 258 Fibromatosis, 57, 60, 61 Fibronectin, 17 Fibrosarcoma, 60, 61, 153, 258, 276, 277, 287, 296 Fibrous hamartoma of infancy, 274, 276 Fibrous histiocytoma, 143, 153, 211, 215, 247, 269, 287, 293, 294 "Field defect" hypothesis, 121 Florid basal cell hyperplasia, 206 Foamy gland variant, 175 Foamy variant, PIN, 196 Frasier syndrome, 51 Fuhrman system, 27 Fungal toxins, 12 G Genital lentiginosis, 292 Genitourinary malformation, 51 Gnomic imprinting, 52, 225 Germ cell tumours, 10, 87, 160, 213, 217, 218, 221, 226, 227 Germ cell-sex cord/gonadal stromal tumour, unclassified, 218, 261 GFAP, 47, 247 Giant cell fibroblastoma, 293, 294, 297 Giant condyloma, 289 Giant multilocular prostatic cystadenoma, 213 Gleason grading, 169, 170, 179-183 Gleason pattern, 180-185, 200 Glomus tumour, 293, 294, 297 Glutathione S-transferase M1, 94 Glutatione S-transferase M1 null genotype, 13 Gonadoblastoma, 218, 260, 261 Gonadotropin, 14, 103, 224, 236, 242, 255 Gonadotropin, human chorionic, 220, 224, 233, 235, 242-249 Granular cell renal cell carcinoma, 23 Granular cell tumour, 145, 160, 209, 211, 274, 293-297 Granulosa cell tumour, 218, 251, 256- 259 Grawitz tumour, 23 GSTP1, 197 Gynecomastia, 13, 14, 224,242, 251, 255-259 H H19, 123 Haemangioblastoma, 15-17, 272 Haemangioma, 10, 71, 90, 141, 146, 153, 157, 160, 209, 293-297 Haemangiopericytoma, 10, 62, 75, 79, 144, 160, 215 Haemangiosarcoma, 64 Haematopoietic and lymphoid tumours, 10, 90 Hamartin, 67 hCG, See Gonadotropin, human chorionic Hemihypertrophy, 51, 52 Hepatocyte growth factor, 17, 18 Hepatosplenomegaly, 13 HER2, 25, 34, 105, 106, 108, 109, 122, 126 Herceptin, 105 Hereditary leiomyomatosis, 18 Hereditary leiomyomatosis and renal cell cancer syndrome, 18-20 Hereditary nonpolyposis colon cancer, 103, 152 Hereditary papillary renal carcinoma, 17, 18 Hibernoma, 153 HIF-1, 17 High grade intraurothelial neoplasia, 119 HLRCC, See Hereditary leiomyomatosis and renal cell cancer syndrome HMB45, 66, 68-70, 146, 273, 279 HMB50, 66 Hodgkin lymphoma, 12, 84, 85, 147, 157, 212, 298 Homer Wright rosettes, 84 Horseshoe kidney, 81 HPC2/ELAC2, 184, 186 HPV, 127, 154, 155, 228, 283, 284, 286- 291 HRAS, 105, 126 hSNF5, 59 hSNF5/INI1, 59 Human glandular kallikrein 2, 167 Hydronephrosis, 85, 95, 147, 152 Hypercalcemia, 13, 85, 135 Hypernephroma, 23 Hyperreninism, 47 Hypertension, 13, 46-48, 62, 72, 73, 85, 137, 214 Hypoglycemia, 62, 215 Hypospadias, 223, 257 Hypoxia-inducible factor (HIF) 1, 17 I IGF2, 61 IL-8, 25 Immature teratoma, 244 Immunosuppression, 85 Infantile fibromatosis, 60 Infantile fibrosarcoma, 60 Infiltrating urothelial carcinoma, 90, 93, 97, 98, 102, 103 Infiltrating urothelial carcinoma with glandular differentiation, 98 Infiltrating urothelial carcinoma with squamous differentiation, 97 Inflammatory pseudotumour, 102, 140, 145, 157 Inherited cancer syndromes, 9, 15 Inhibin, 232, 243, 251, 252, 254, 256, 257, 260, 261 INI1, 59 Insulin-like growth factor (IGF)-2, 61 Insulin-like growth factor 1 receptor, 61 Interstitial cell tumour, 251 Intestinal metaplasia of the urothelium, 129 Intralobar nephrogenic rests, 54 Intratubular germ cell neoplasia, unclassified, 223 Inverted papilloma, 99, 114, 115, 138, 153, 156 Inverted urothelial papilloma, 90 Inverted variant, PIN, 196 IGCNU, 223, 225, 228-231, 234, 244 Subject index 355
J Juvenile type granulosa cell tumour, 218, 257 Juvenile xanthogranuloma, 293, 297 Juxtaglomerular cell hyperplasia, 46, 47 Juxtaglomerular cell tumour, 10, 72, 73 K KALK13, 225 Kaposi sarcoma, 141, 144, 146, 267, 275, 282, 293, 294, 296, 297 Ki-67 antigen, 113, 123, 130, 192, 206 Kidney cysts, 15, 16 Klinefelter syndrome, 251 Klipel-Trenaunnay-Weber syndrome, 146 Klippel-Trenaunay syndrome, 51, 71 KRAS2, 226, 227 L Lactate dehydrogenase, 220, 224 Large cell calcifying Sertoli cell tumour, 218, 253, 255 Large cell undifferentiated carcinoma, 103 LDH, See Lactate dehydrogenase Lectin, 34 Leiomyoma, 10, 70, 144, 211, 215, 276, 293, 294 Leiomyomas of the skin and uterus, 18 Leiomyosarcoma, 19, 63, 140, 210, 215, 275, 294, 296 Leiomyosarcoma of the uterus, 19 Leu M1, 100, 268, 270, 271 Leukaemia, 10, 87, 160 Leydig cell tumour, 218, 251-253, 256, 258, 259 Lichen sclerosus, 282, 289, 290 Lipid-cell variant, urothelial carcinoma, 103 Lipoma, 21, 153, 274, 276 Liposarcoma, 64, 66, 102, 103, 144, 160, 178, 215, 274-276 Littre glands, 90, 155 Low grade papillary urothelial carcinoma, 104, 113 Lymphangioleiomyomatosis (LAM), 65 Lymphangioma, 10, 71, 270, 293, 294, 297 Lymphangioma circumscriptum, 295 Lymphoepithelioma-like carcinoma, 100, 101, 103, 108, 135 Lymphoepithelioma-like variant, 177 Lymphoma-like variant, urothelial carcinoma, 101 Lynch syndrome, 152 M Macroglossia, 52 MAK6, 40 Malakoplakia, 172, 252 Maldescended testes, 223 Male adnexal tumour of probable Wolffian origin, 160 Male angiomyofibroblastoma-like tumour, 275 Male infertility, 223 Malignant epithelial-stromal tumour, 214 Malignant fibrous histiocytoma, 10, 64, 90, 143, 160, 209, 215, 275-277, 293-297 Malignant Leydig cell tumour, 252 Malignant lymphoma, 101, 135, 147, 221 Malignant melanoma, 90, 146, 157, 213, 292 Malignant mesothelioma, 218, 268-270 Malignant peripheral nerve sheath tumour, 144, 145, 160, 247, 293, 297 Malignant Sertoli cell tumour, 218, 256 Malignant teratoma, undifferentiated, 237 MALT lymphoma, 147, 265 MAP kinase, 61 Mart1/Melan A, 66 Mature teratoma, 218, 244, 245 MDM2, 105, 108, 136, 226, 241 Medulloepithelioma, 247 Melanocytic markers, 66, 69 Melanocytic nevus, 90, 281, 292 Melanotic hamartoma, 272 Melanotic neuroectodermal tumour, 218, 272, 273 Melanotic progonoma, 272 Merkel cell carcinoma, 281, 288 Merkel cell tumour, 279 Mesangial sclerosis, 51 Mesoblastic nephroma, 52 Mesonephric carcinoma, 133 MET, 15, 18, 108, 188 Metalloproteinase 2, 17 Metalloproteinase 2 (TIMP-2), 17 Metanephric adenofibroma, 10, 44-46 Metanephric adenoma, 10, 44-46 Metanephric adenosarcoma, 44 Metanephric stromal tumour, 10, 46, 47 MFH, See Malignant fibrous histiocytoma MHC class II, 25 MIB-1, 133, 145, 252 MIC2 (CD99), 57 Michaelis Gutman bodies, 252 Microophthalmia transcription factor, 66 Micropapillary carcinoma, 100 Micturition attacks, 137, 214 Mixed embryonal carcinoma and teratoma, 218 Mixed epithelial and stromal tumour, 10, 77, 78 Mixed gonadal dysgenesis, 257, 260 Mixed mesenchymal and epithelial tumours, 10 Mixed teratoma and seminoma, 218 MLH1, 152 MMP-2, 25 MMP-9, 25 Monodermal teratoma, 218, 244-246 Monophasic choriocarcinoma, 218, 241, 243 Monosomy X, 71 MSH2, 152 MSH3, 152 MSH6, 152 MSR1, 184, 186 MST, 46, 47 MUC3, 24 MUC5AC, 98 MUCI, 24 Mucinous (colloid) adenocarcinoma, 176 Mucinous borderline tumours, 262 Mucinous carcinomas, 132 Mucinous cystadenocarcinoma, 218 Mucinous cystadenoma, 218 Mucinous tubular and spindle cell carcinoma, 10, 40 Mucinous variant, PIN, 196 Mucosal papules, 21 Multifocal bladder neoplasms, 121 Multilocular clear cell renal cell carcinoma, 10 Multilocular cyst, 213 Multilocular cystic renal cell carcinoma, 26 356 Subject index
- Page 1 and 2:
World Health Organization Classific
- Page 3 and 4:
This volume was produced in collabo
- Page 5 and 6:
Contents 1 Tumours of the kidney 9
- Page 7 and 8:
CHAPTER 1 Tumours of the Kidney Can
- Page 9 and 10:
TNM classification of renal cell ca
- Page 11 and 12:
one quarter of kidney cancers in bo
- Page 13 and 14:
Familial renal cell carcinoma M.J.
- Page 15 and 16:
Table 1.02 Genotype - phenotype cor
- Page 17 and 18:
A B Fig. 1.11 A Multiple cutaneous
- Page 19 and 20:
A B Fig. 1.14 Birt-Hogg-Dubé syndr
- Page 21 and 22:
Clear cell renal cell carcinoma D.J
- Page 23 and 24:
Fig. 1.20 Clear cell renal cell car
- Page 25 and 26:
Papillary renal cell carcinoma B. D
- Page 27 and 28:
A B Fig. 1.29 Papillary renal cell
- Page 29 and 30:
Fig. 1.33 Chromophobe RCC with sarc
- Page 31 and 32:
Carcinoma of the collecting ducts o
- Page 33 and 34:
Renal medullary carcinoma C.J. Davi
- Page 35 and 36:
Renal carcinomas associated with Xp
- Page 37 and 38:
Renal cell carcinoma associated wit
- Page 39 and 40:
Papillary adenoma of the kidney J.N
- Page 41 and 42:
of this tumour. Microscopic extensi
- Page 43 and 44:
A B Fig. 1.59 Metanephric adenoma.
- Page 45 and 46:
esults in intratumoral aneurysms. O
- Page 47 and 48:
peritumoural fibrous pseudocapsule.
- Page 49 and 50:
increases in prevalence to approxim
- Page 51 and 52:
Nephrogenic rests and nephroblastom
- Page 53 and 54:
Cystic partially differentiated nep
- Page 55 and 56:
A B Fig. 1.80 Clear cell sarcoma of
- Page 57 and 58:
A B Fig. 1.85 Rhabdoid tumour of th
- Page 59 and 60:
transcription factor is fused to th
- Page 61 and 62:
Leiomyosarcoma S.M. Bonsib Definiti
- Page 63 and 64:
Angiomyolipoma G. Martignoni M.B. A
- Page 65 and 66:
melanocytic and smooth muscle marke
- Page 67 and 68:
Multinucleated and enlarged ganglio
- Page 69 and 70:
Haemangioma P. Tamboli Definition H
- Page 71 and 72:
Fig. 1.107 Juxtaglomerular cell tum
- Page 73 and 74:
Intrarenal schwannoma I. Alvarado-C
- Page 75 and 76:
Mixed epithelial and stromal tumour
- Page 77 and 78:
Synovial sarcoma of the kidney J.Y.
- Page 79 and 80:
Renal carcinoid tumour L.R. Bégin
- Page 81 and 82:
Primitive neuroectodermal tumour (E
- Page 83 and 84:
Paraganglioma / Phaeochromocytoma P
- Page 85 and 86:
Leukaemia A. Orazi Interstitial inf
- Page 87 and 88:
WHO histological classification of
- Page 89 and 90:
TNM classification of carcinomas of
- Page 91 and 92:
The risk of bladder cancer goes dow
- Page 93 and 94:
Tumour spread and staging Urinary b
- Page 95 and 96:
feature in such patients undergoing
- Page 97 and 98:
A Fig. 2.12 Infiltrative urothelial
- Page 99 and 100:
A Fig. 2.15 A Infiltrating urotheli
- Page 101 and 102:
A B Fig. 2.19 A Infiltrative urothe
- Page 103 and 104:
Fig. 2.23 Infiltrative urothelial c
- Page 105 and 106:
ing systems have been proposed on t
- Page 107 and 108:
Non-invasive urothelial tumours G.
- Page 109 and 110:
chronically inflamed urothelium and
- Page 111 and 112:
Inverted papilloma G. Sauter Defini
- Page 113 and 114:
muscle invasive disease, but there
- Page 115 and 116:
Fig. 2.42 Non-invasive urothelial n
- Page 117 and 118:
A Fig. 2.45 Non-invasive urothelial
- Page 119 and 120:
for DBCCR1 silencing {984,2476}. Th
- Page 121 and 122:
Squamous cell carcinoma D.J. Grigno
- Page 123 and 124:
Fig. 2.51 Squamous cell carcinoma.
- Page 125 and 126:
Adenocarcinoma A.G. Ayala P. Tambol
- Page 127 and 128:
A B Fig. 2.61 A Adenocarcinoma in s
- Page 129 and 130:
A B Fig. 2.65 Intramural urachal ca
- Page 131 and 132:
Müllerian origin is postulated for
- Page 133 and 134:
A Fig. 2.69 Small cell carcinoma. A
- Page 135 and 136:
Carcinoid L. Cheng Definition Carci
- Page 137 and 138:
Leiomyosarcoma J. Cheville Definiti
- Page 139 and 140:
Osteosarcoma L. Guillou Definition
- Page 141 and 142:
Leiomyoma J. Cheville Definition A
- Page 143 and 144:
Haemangioma L. Cheng Definition Hae
- Page 145 and 146:
Metastatic tumours and secondary ex
- Page 147 and 148:
Tumours of the renal pelvis and ure
- Page 149 and 150:
nodular, ulcerative or infiltrative
- Page 151 and 152:
Tumours of the urethra F. Hofstädt
- Page 153 and 154:
usually show enteric, colloid or si
- Page 155 and 156:
CHAPTER 3X Tumours of of the the Pr
- Page 157 and 158:
TNM classification of carcinomas of
- Page 159 and 160:
contrast, mortality among migrants
- Page 161 and 162:
Fig. 3.06 Transrectal ultrasound of
- Page 163 and 164:
PSA-related diagnostic strategies.
- Page 165 and 166:
A B C Fig. 3.10 A,B Section of pros
- Page 167 and 168:
pale-clear, similar to benign gland
- Page 169 and 170:
A B Fig. 3.20 A, B Adenocarcinoma w
- Page 171 and 172:
prostate adenocarcinomas exhibit AR
- Page 173 and 174:
A Fig. 3.27 A, B Foamy gland adenoc
- Page 175 and 176:
A B Fig. 3.32 A Sarcomatoid carcino
- Page 177 and 178:
A B Fig. 3.37 A Gleason score 1+1=2
- Page 179 and 180:
A B Fig. 3.43 A Prostate cancer Gle
- Page 181 and 182:
Fig. 3.48 Heat map-nature. From S.M
- Page 183 and 184:
Fig. 3.51 Prostate cancer. Major su
- Page 185 and 186:
many stage T1b cancers. Stage T2 Mo
- Page 187 and 188:
Fig. 3.58 Patterns of seminal vesic
- Page 189 and 190:
Prostatic intraepithelial neoplasia
- Page 191 and 192:
A B Fig. 3.63 A Micropapillary high
- Page 193 and 194:
A B Fig. 3.68 A Ductal carcinoma in
- Page 195 and 196:
Ductal adenocarcinoma X.J. Yang L.
- Page 197 and 198:
Papillary pattern can be seen in bo
- Page 199 and 200:
A B Fig. 3.74 A Inflammation withou
- Page 201 and 202:
Squamous neoplasms T.H. Van der Kwa
- Page 203 and 204:
Neuroendocrine tumours P.A. di Sant
- Page 205 and 206:
Mesenchymal tumours J. Cheville F.
- Page 207 and 208:
Fig. 3.89 Sarcoma of the prostate.
- Page 209 and 210:
Miscellaneous tumours P.H. Tan L. C
- Page 211 and 212:
A Fig. 3.96 A Adenocarcinoma of the
- Page 213 and 214:
WHO histological classification of
- Page 215 and 216:
Introduction F.K. Mostofi I.A. Sest
- Page 217 and 218:
wartime birth cohorts illustrate th
- Page 219 and 220:
Similar tumours as those of group 1
- Page 221 and 222:
crucial for the development of this
- Page 223 and 224:
A B Fig. 4.09 Spermatocytic seminom
- Page 225 and 226:
A B Fig. 4.14 Intratubular germ cel
- Page 227 and 228:
A B Fig. 4.19 Seminoma. A Typical s
- Page 229 and 230:
Fig. 4.24 Seminoma. Vascular invasi
- Page 231 and 232:
Fig. 4.28 Spermatocytic seminoma wi
- Page 233 and 234:
A B Fig. 4.33 Embryonal carcinoma.
- Page 235 and 236:
A B Fig. 4.38 Yolk sac tumour. A En
- Page 237 and 238:
have cytoplasmic lacunae that conta
- Page 239 and 240:
A Fig. 4.46 Teratoma. A Longitudina
- Page 241 and 242:
A B Fig. 4.51 A Cut surface of derm
- Page 243 and 244:
Fig. 4.54 Mixed germ cell tumour. L
- Page 245 and 246:
Sex cord / gonadal stromal tumours
- Page 247 and 248:
A B C Fig. 4.67 Malignant Leydig ce
- Page 249 and 250:
A Fig. 4.73 A Sertoli cell tumour.
- Page 251 and 252:
ICD-O codes Granulosa cell tumour 8
- Page 253 and 254:
ICD-O code 8592/1 Clinical features
- Page 255 and 256:
A B Fig. 4.83 Germ cell-sex cord/go
- Page 257 and 258:
A Fig. 4.85 A, B Brenner tumour of
- Page 259 and 260:
typical grade III follicular morpho
- Page 261 and 262:
testicular parenchyma and tumour te
- Page 263 and 264:
A B the surgical scar and adjacent
- Page 265 and 266:
Immunoprofile Ordóñez and associa
- Page 267 and 268:
often have a grey-white cut surface
- Page 269 and 270:
Fig. 4.111 Angiomyofibroblastoma-li
- Page 271 and 272:
A B Fig. 4.119 Embryonal rhabdomyos
- Page 273 and 274:
Table 4.05 Secondary tumours of the
- Page 275 and 276:
WHO histological classification of
- Page 277 and 278:
A Fig. 5.04 A, B Squamous cell carc
- Page 279 and 280:
deformed by an exophytic mass. In s
- Page 281 and 282:
A B C Fig. 5.12 A Warty (condylomat
- Page 283 and 284:
A Fig. 5.20 Bowenoid papulosis. A,
- Page 285 and 286:
three had been circumcized by 9 yea
- Page 287 and 288:
Mesenchymal tumours J.F. Fetsch M.
- Page 289 and 290:
Fig. 5.31 Neurofibroma of the penis
- Page 291 and 292:
oectodermal tumour/Ewing sarcoma [p
- Page 293 and 294:
Secondary tumours of the penis C.J.
- Page 295 and 296:
Dr John N. EBLE* Dept. of Pathology
- Page 297 and 298:
Dr Ricardo PANIAGUA Department of C
- Page 299 and 300: Source of charts and photographs 1.
- Page 301 and 302: References 1. Anon. (1955). Case re
- Page 303 and 304: 115. Ariel I, Sughayer M, Fellig Y,
- Page 305 and 306: 246. Birt AR, Hogg GR, Dube WJ (197
- Page 307 and 308: 374. Cardone G, Malventi M, Roffi M
- Page 309 and 310: 502. Corti B, Carella R, Gabusi E,
- Page 311 and 312: 633. Donhuijsen K, Schmidt U, Richt
- Page 313 and 314: 768. Fischer J, Palmedo G, von Knob
- Page 315 and 316: 900. Goedert JJ, Cote TR, Virgo P,
- Page 317 and 318: 1028. Hartmann A, Dietmaier W, Hofs
- Page 319 and 320: 1162. Iezzoni JC, Fechner RE, Wong
- Page 321 and 322: 1293. Keetch DW, Catalona WJ (1995)
- Page 323 and 324: 1424. Ladanyi M, Lui MY, Antonescu
- Page 325 and 326: 1548. Lopez-Beltran A, Croghan GA,
- Page 327 and 328: 1681. McLaughlin JK, Silverman DT,
- Page 329 and 330: 1816. Moudouni SM, En-Nia I, Rioux-
- Page 331 and 332: 1945. Ohori M, Wheeler TM, Kattan M
- Page 333 and 334: 2070. Phillips G, Kumari-Subaiya S,
- Page 335 and 336: 2199. Riou G, Barrois M, Prost S, T
- Page 337 and 338: 2327. Schmidt L, Junker K, Weirich
- Page 339 and 340: 2450. Smith G, Elton RA, Beynon LL,
- Page 341 and 342: 2572. Tamboli P, Mohsin SK, Hailema
- Page 343 and 344: 2693. van Echten J, Timmer A, van d
- Page 345 and 346: 2816. Wick MR, Berg LC, Hertz MI (1
- Page 347 and 348: 2937. Zhuang Z, Park WS, Pack S, Sc
- Page 349: CCNB, 226 CCND1, 105, 108 CCND2, 22
- Page 353 and 354: Promoter methylation, 21 Prostate s